Danaher (DHR) Looks to Expand Molecular Diagnostics Business with $4 Billion Acquisition of Cepheid
From its headquarters in Washington, DC, Danaher Corporation (NYSE: DHR) announced on Tuesday, September 6, 2016, that it will be merging with Cepheid (NASDAQ: CPHD) in a deal valued at close to $4 billion. The acquisition, when completed in the fourth quarter, is expected to expand Danaher’s $5 billion diagnostics business by over 10 percent. Under the terms of the agreement, Danaher will acquire, for cash, all of the outstanding shares of Cepheid at $53.00 per share. The acquisition price represents a 54 percent premium on Cepheid’s Friday closing price of $34.42 per share, which, based on the 72.9 million…